Beta-Lactam
Phase 3Small molecule
RocheBeta-Lactam is one of 54 small molecule programs targeting Bacterial Pneumonia. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Bacterial Pneumonia
#DrugCompanyPhaseTrials
1Teflaro
AbbVieApproved
Biaxin
AbbVieApproved
Ketek
SanofiApproved
Levaquin
WWim Janssens
Approved
Avelox
BayerPhase 3
Zyvox
PfizerPhase 3
Avycaz
PPhiladelphia Eye Associates
Approved
Amikin
IInsmed Incorporated
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Primaxin
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Staphylococcus aureus infection1 trial
Hospitalized Patients1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beta-Lactam. EMBL-EBI & Wellcome Sanger Institute.
- [4]